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Abstract
Background: Uveal Melanoma (UM) although a rare disease, causes high mortality due to 
metastases. Long-term prognosis may be estimated based on the genetic profile of the UM tumor, 
however, lack of effective and specific treatment prevents cure.
Methods: This review summarizes current knowledge and outlines future directions relevant to UM 
metastatic disease.
Results: The overall consensus is that UM micrometastases remain dormant for a number of years, 
before actively proliferating and becoming detectable clinically. The main site of UM metastases is 
the liver, constituting a very specific niche, and numerous molecular factors are involved in UM 
liver homing, like CXCL12-CXCR4.
Conclusion: New avenues of research must include the mechanism of UM cells seeding from the 
primary tumor, homing to the liver, liver invasion, as well as UM cell dormancy.
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Introduction
Melanoma is a relatively rare tumor originating from melanocytes and developing in various 
locations: The skin and mucosa (of the nose, nasopharynx, lungs, stomach, intestines, vagina, 
rectum and urinary tract), the conjunctiva of the eye, uvea, eyelids, and orbit. Uveal Melanoma 
(UM) is a neoplasm thought to have developed from neoplastic melanocytes of the uvea [1,2].
UM is the most common primary intraocular neoplasms in adults. In the USA, the mean age-
adjusted incidence is 5.1 per million [3,4]. The UM incidence in Europe depends on the latitude, 
and is higher in Northern Europe (≥ 8 cases per million in Norway and Denmark), in comparison 
with Southern Europe (two cases per million in Spain and Italy) [5]. UM very rarely runs in families. 
Single families have been reported to show germline BAP1 mutation in chromosome 3, which 
predisposes them to develop UM and other neoplasms [6]. UM is usually diagnosed in people 
in their 6th decade of life, except for iris melanoma which is identified at an earlier age due to its 
location, most typically in the 5th decade of life, usually 10 to 20 years earlier than ciliary body 
melanoma or choroidal melanoma [7].
Risk factors for the development of uveal melanoma include Caucasian ethnicity, light eye color 
(green or blue), dysplastic nevus syndrome, ocular melanocytosis and presence of germline BRCA1-
Associated Protein 1 (BAP1) mutations [8-11].
UM represents about 85% of all ocular melanomas and is biologically distinct from Cutaneous 
Melanoma (CM) [12,13]. CM has been gradually increasing since the 1970s, whereas the incidence 
of uveal melanoma has remained stable for many years [4,5]. The TNM (Tumor-Node-Metastasis) 
staging system, developed by the American Joint Committee on Cancer (AJCC) was based on 
collated approximately 9000 UM cases across Europe [14]. Shields et al. [8] studying another large 
group of UM patients determined that metastatic disease developed in only 5% patients with small 
tumors up to 1 mm thick, in 10% patients with tumors up to 2 mm thick and in 30% patients with 
tumors 6 mm thick. Up to 50% of patients develop metastatic disease (dissemination of UM), which 
are most frequently located in the liver.
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Long-term Prognosis in UM is Determined 
by Metastasis
It is well known that the life expectancy of UM patients is 
independent of the local tumor control and results from the 
development of metastases. The 10-year survival rates are 57% and 
15-year survival rates are 50% [15]. These numbers have remained 
unchanged for many years, despite the improvements in the treatment 
of the primary disease [16]. This is because it is the progression of 
the disease in the liver that determines the clinical course of uveal 
melanoma.
The time-course of metastatic detection is varied and may even 
take a few years, at 5 years is estimated to be 32%, at 15 years 50% 
and 25 years 56 % [15]. Lower metastatic rates have been found in 
younger patients [17].
Metastases from uveal melanoma appear in 8% to 32% of the 
patients during the first 5 years and in 50% of the patients at 10 
years after diagnosis of the primary tumor [15,17,18]. When liver 
metastases develop, the prognosis is poor and life expectancy reduces 
to 6 to 11 months and only 15% of patients are alive after more than 
1 year [19,20].
The liver is the first site of systemic metastasis for 89% to 95% of 
patients and the exclusive site of systemic metastasis in more than 
50% of patients. In approximately half of the cases also the lungs 
(24%), bone (16%), and skin (11%) may be involved. Very rarely 
metastases are found in lymph nodes (10%) and brain (5%) [21-24].
Recurring uveal melanoma patients’ median survival time is less 
than 6 months from metastasis detection, regardless of treatment, 
and the one-year survival rate is estimated to be 10% to 15%. In 
contrast, a longer survival of about 19 to 28 months was found in 
patients with metastatic melanoma restricted to extra hepatic sites, 
and 76% of the patients survive over a year [25,26]. The latest deaths 
due to UM metastases occur between 10 and 18 years after diagnosis, 
but metastases after 40 years were also reported [15]. TOOT study 
provided evidence that local recurrence significantly increases the 
risk of metastasis despite the type of primary tumor treatment [27].
The mortality pattern of UM patients, regardless of treatment, 
presents a characteristic bimodal time-course with 1st peak at 2 to 4 
years, and the second at 8 to 9 years after treatment [28]. A small 
percentage of patients have a delayed recurrence, at more than 10 
years, and this correlates with longer survival [26]. It seems that these 
tumors grow more slowly. The mortality due to metastasis strongly 
correlates with the size of the tumor, as the percentage of deaths due 
to metastatic disease increased from 15% to 82% with the increase in 
basal diameter from less than 10 to greater than 18 mm [29].
The high mortality rate results from the lack of effective treatments 
for metastatic disease. Available options include resection of liver or 
chemotherapy. The general response rate for chemoembolization 
in uveal melanoma patients was 36%, compared with less than 
1% in those treated with systemic chemotherapy [30]. Systemic 
chemotherapy is usually unsuccessful in metastatic uveal melanoma 
and results in an objective response rate that ranges from 5% to 15% 
[20].
The percentage of patients with metastases depends very strongly 
on the tumor thickness and its cytogenetics or genetic profile. 
Metastases were detected at 10 years after diagnosis in 12% of patients 
if the tumor was <3 mm, in 26% of patients of the tumor was 3 mm to 
8 mm, and in 49% if the tumor was >8 mm [31].
An increased risk of metastasis and a poor prognosis in UM 
is connected with loss of one copy of chromosome 3 (monosomy 
3, M3) [31]. Other chromosome abnormalities, amplification of 
chromosome 8q, loss of chromosome 1p, and gain of chromosome 
6p, have been identified as prognostic parameters in UM [32]. 
Increased copy number of 8q precedes the loss of chromosome 3 [33]. 
Adding chromosome 3 and 8 status to AJJC grading of UM allows 
for more accurate prognostication [34,35]. Another approach is a 12-
gene microarray-based gene expression panel to determine whether a 
patient is in a low- or a high-risk prognostic group [36].
Recently, a comprehensive genome, RNA, proteomics, and 
immune infiltrate analysis identified 4 distinct subsets of UM, i.e. (i) 
D3-UM tumors with EIF1AX mutation (low risk) or (ii) D3-UM with 
SF3B1 mutation (intermediate risk), correlated with distinct DNA 
methylation and SCNA profiles. D3-UM tumors also separated into 
two groups by transcription (mRNA, lncRNA, and miRNA) profile 
analysis. The other two groups (iii) and (iv) were M3/BAP1 (with 
biallelic BAP1 loss) with poor prognosis. M3/BAP1 aberrancy is 
associated with a global DNA methylation profile that is not observed 
in D3-UM. Despite all M3/BAP1-aberrant UM sharing this common 
DNA methylation pattern, these tumors divide into two groups by 
SCNA and transcription profiles, with distinct pathway features 
indicative of hypoxia, DDR, MYC/MAX signaling, and proliferation. 
The group M3/BAP1 loss group with the worse prognosis is 
characterized by the up-regulation of hypoxia, DNA damage repair, 
MYC, and down regulation of MAPK/PI3K, FOXA1/M1 and E2F1 
pathways [37].
Most UM harbor one Gq pathway mutation (GNAQ, GNA11, 
CYSLTR2, or PLCB4), one BSE mutation (BAP1, SF3B1, or EIF1AX), 
and a few recurrent copy number aberrations, in 100% of tumor cells. 
These canonical changes usually occur relatively early in the tumor 
development, suggesting that metastatic abilities of the tumor may 
be determined early, maybe even before the detection of the primary 
mass. This would explain the lack of improvement in survival rates 
despite advances in diagnosis and treatment [38]. The genetic 
background of UM also determines the inflammatory environment, 
with gain of chromosome 8q leading to macrophage infiltration, while 
sequential loss of BAP1 expression drives T cell infiltration [39].
There is a very limited array of management options for patients 
with metastatic uveal melanoma. In a few cases, liver resection is 
possible. The available options have been reviewed in [21,40,41]. Local 
chemotherapy of different drug combinations has been applied with 
poor results to date [21,42-44]. The interim results of a clinical trial 
in immunotherapy, based on adoptive transfer of autologous tumor 
infiltrating lymphocytes in patients with metastatic uveal melanoma 
seem to be promising [45]. Other immunotherapy options are being 
explored [46,47]. High hopes for CTLA4 and PD-1 checkpoint 
immunotherapy so far have not been confirmed [48], however, 
recently a strong response with metastasis burden decrease was 
observed in a single UM patient with an MBD4 mutation [49]. This 
might open up a new avenue of research for effective immunotherapy 
in UM metastatic disease. There are several clinical trials enrolling 
subgroups of metastatic UM patients.
UM Metastases to the Liver
UM developing in the choroid spreads hematogenously mainly 
to the liver (Figures 1 and 2A-2D). Hematogenous metastatic 
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spread is a multi-step process, including arrest by size restriction 
in micro vessels, rapid extravasation, and perivascular positioning, 
followed by single-cell dormancy or growth to micro metastatic 
and macro metastatic stage [50]. UM cell lines did not show a high 
pro-hemangiogenic potential, suggesting that other factors like the 
anatomy of ocular lymphatics seem to be responsible. The extraocular 
conjunctiva and limbus are well-endowed with lymphatic vessels, and 
the inner eye is physiologically devoid of these vessels. Therefore only 
when UM has grown outside the eye, may the cells find their way into 
the lymph system [51].
Romanowska-Dixon et al. [52] described the routes of extraocular 
extension via emissary channels of the sclera, like muffs surrounding 
vessels or other perforators (aqueous channels, ciliary arteries, ciliary 
nerves, optic nerve, vortex veins). All ‘locus minoris resistances” make 
extraocular invasion of UM cells easier, regardless of the cell type 
[52]. They have shown the routes of extension without sclera invasion 
or with lamellar sclera infiltration in the group of 170 patients with 
intraocular tumor size between 1.5 mm to 15 mm. The extrascleral 
extension was detectable with ultrasound/ultrabiomicroscopy before 
enucleation in 18% of patients with extraocular tumor invasion [53].
Damato pointed out the many possible hypotheses formed on 
how metastases develop in UM and whether or not the treatment 
influences survival. He proposed that UM are consisting of at least 
three groups: (1) metastasizing melanomas, which have already 
metastasized by the time of ocular treatment even though the 
metastases may not be detectable; (2) pre-metastasizing melanomas, 
which develop metastatic capability and disseminate if treatment 
is delayed and (3) non metastasizing melanomas, which do not 
metastasize, even if never treated [54]. In the light of the dormancy 
concept however, one may speculate that all UM are in the first group, 
but that in some cases the metastases remain dormant for many years.
It is believed that micrometastatic disease precedes local therapy, 
remaining dormant for a long time. Moreover, there is a correlation 
between metastatic risk and the size of the tumor [29], suggesting 
that metastatic seeding might occur over the whole time of the tumor 
growth. Therefore the results of Damato et al. [29] from analyzing 
a large group of patients pointing out that early treatment of UM 
should prevent metastatic spread in some patients are in accordance 
with this hypothesis.
Eskelin et al. [55] estimated that micro metastases from uveal 
melanoma could develop as early as 5 years before the treatment of 
the primary tumor. At this estimated time of micro metastases, the 
theoretically estimated size of the primary tumor would be app. 3 mm 
in diameter and 1.5 mm in height or only 7 mm 3 in volume [55].
The current concept in cancer cell dissemination is that there 
are several cancer cell migration modes, i.e. single cell, multi cellular 
streaming and cell clusters, containing both tumor and stromal cells 
[56]. Analysis of the structure of liver from UM patients revealed 
the presence of single cells, as well as micrometastases and macro-
metastases [57-60]. Both single cells and cell clusters were detected in 
the blood of UM patients [61].
Grossniklaus et al. [57] have been studying the structure of liver 
metastases both in the animal model [62], and in the clinical samples 
[57,58]. They describe the hypothetical metastasis progression from 
single cells, having cancer stem cell-like characteristics. The presence 
of CD45/CD133 individual UM cells were shown in the sinusoidal 
space, portal venule and periportal area, suggesting they are the 
precursors to metastases [58].
The liver UM metastases result in two distinct growth patterns: 
Figure 1: UM metastases appear in 50% of patients within 10 years of 
diagnosis of the primary tumor. The liver is the preferred metastatic site (89% 
to 95%). In approximately half of the cases also the lungs (24%), bone (16%), 
and skin (11%) may be involved. Very rarely metastases are found in lymph 
nodes (10%) and brain (5%).
Figure 2: (A,B) Histology of a liver uveal melanoma metastasis. Uveal 
melanoma cells are seen invading normal liver. (C,D) Immunohistochemistry 
against HMB45 (brown) confirming presence of uveal melanoma cells in 
the liver lesion. (E,F) Cell lines derived from a single UM liver metastasis 
showing different cell morphology: Cells UM15.4.1 of epitheloid character (E) 
and UM15.6.3 of spindle shape (F).
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The infiltrative and nodular growth patterns. In the infiltrative 
pattern, melanoma invades the sinusoidal space, replaces the hepatic 
lobule, is essentially avascular, and does not express VEGF. These 
lesions generate MMP, leading to the creation of pseudosinusoidal 
spaces providing tumor oxygenation. In the nodular growth pattern, 
melanoma arises in the periportal area, coopts the portal venule, and 
eventually grows, becomes hypoxic, expresses MMP9 and VEGF, 
undergoes angiogenesis, and effaces the adjacent hepatocytes. The 
authors proposed that infiltrative growth is controlled in part by 
changes in the immune microenvironment in the sinusoidal space 
and nodular growth is controlled in part by the microenvironment 
VEGF: PEDF ratio in the periportal area [58]. UM cell aggregates have 
enhanced adhesion due to proinflammatory factors release, and later 
on activate hepatic stellate cells to myofibroblasts that form a scaffold 
for the metastasis to grow [57]. The same authors also attempted to 
correlate the histological results from biopsies with non-invasive MRI 
of liver lesions [63].
Some authors suggest that both perivascular and intravascular 
migration can contribute to the spreading of metastatic cells in the 
target organ [50,60]. During liver colonization individual tumor cells 
initially migrate inside or along sinusoids until a critical local cell 
density is reached and growth initiates [50]. In another study, using 
international consensus guidelines the histopathological growth 
patterns of liver metastases were studied in resected livers from UM 
patients [60]. For 41 liver metastases, 30 (73%) were classified as a 
predominant replacement pattern (where tumor cells were replacing 
liver cells), while 11 (27%) as a predominant desmoplastic pattern 
(tumor cells form a nodule, separated by a fibrotic tissue from 
surroundings). In a similar fashion to colorectal and breast carcinoma, 
the replacement pattern significantly predicted diminished survival 
while the desmoplastic pattern correlated with increased survival. 
The genomic high-risk variable had no prognostic value at this stage 
of liver metastasis. In the replacement pattern tumor cells occupy 
‘vascular niches’, such as the space of Disse. What is interesting, 
the melanoma cells located in the vicinity of sinusoidal vessels were 
localized to the abluminal vascular surfaces of sinusoidal vessels and 
in the space of Disse, rather than being intraluminal [59,60]. These 
results might provide a prognostic marker for the metastatic patients 
if they could be related to radiologic parameters.
The role of hepatic stellate cells in creating the metastatic 
niche has been suggested [64]. The hepatic stellate cells may 
transdifferentiate into myofibroblasts and secrete proinflammatory 
factors and collagen. In the mouse xenograft model, the number 
of hepatic metastases was increased when human HSteCs were co-
inoculated, leading to an increase in fibrillar collagen production. The 
presence of activated hepatic cells and their pathological matrix were 
also localized surrounding the UM lesions in patient hepatectomy 
samples [64].
The research on UM metastasis mechanisms and UM treatments 
efficacies are hampered by lack of appropriate UM models. Only a 
few stabilized cell lines and PDX are available [65-67]. An example of 
stabilized cell lines, derived from a patient metastatic biopsy is shown 
in Figure 2E and 2F.
Dormancy of the Disseminated Tumor Cells
Dormancy can be broadly defined as the process though which 
cells exit the cell cycle and survive in a quiescent state. It is considered 
an evolutionarily conserved mechanism of adaptation to stress 
which allows cells to survive in a hostile microenvironment [68]. 
Disseminated cancer cells are able to persist for years because they 
interpret homeostatic signals from the host microenvironment and 
respond by entering a long-lasting dormant state, with occasional 
cell divisions (cellular dormancy) [69]. Similarly, tumor cells may 
give rise to micrometastatic lesions that are unable to outgrow until 
they avert immunosurveillance and elicit a supportive angiogenic 
response (micrometastatic dormancy) [70,71]. Dormancy may also 
result from an equilibrium between proliferation and apoptosis that 
results in the equilibrium of a subclinical tumor mass (tumor mass 
dormancy) [68].
Regulation of cellular proliferation, autophagy, and modulation 
by metastasis suppressor genes as well as micro environmental cues, 
such as interaction with extracellular matrix, hypoxia, impaired 
angiogenesis, inflammation and immunity are implicated in 
dormancy control [68,69,72].
In cancers other than UM, NR2F1, TGFbeta2 or HES1 seem to 
be involved in inducing or prolonging dormancy [73]. The UPR was 
found to promote the survival of dormant cancer cells and it has 
been linked to how cancer cells respond both to internal (metabolic) 
stress and external stress (adaptation to foreign extracellular 
matrix composition [74]. Another important discovery was that 
the endothelium induced quiescence in breast cancer cells through 
the production of Thrombospondin-1 (TSP-1) but sprouting 
neovasculature induced disseminated cell proliferation mediated by 
the secretion of TGF-β1 and periostin (POSTN) by endothelial tip 
cells [68]. In metastatic spreading of lung and breast cancer cells in 
the perivascular niche it was found that L1CAM and YAP signaling 
enables the outgrowth of metastasis-initiating cells both immediately 
following their infiltration of target organs and after they exit from a 
period of latency [75].
Liver Metastatic Niche
Dormant disseminated tumor cells may reside in specialized 
niches that support their survival, restrain their proliferation and 
finally lead to their reawakening [70,76]. In this they are similar 
to cancer stem cells as they enter into dormancy and eventually 
undergo reactivation in response to niche signals similar to those that 
regulate normal adult stem cells [70,74]. For example, prostate cancer 
cells metastasizing to the bone have been found to compete with 
hematopoietic stem cells for occupancy of sites in the endosteal niche; 
this occurs via the CXCL12-CXCR4 signaling axis that is normally 
reserved for the physiologic regulation of hematopoietic stem cells 
[76]. Primary UM expressing high levels of c-Met and/or CXCR4 
aggregate in the liver, which contains the c-Met ligand, HGF/SF and 
the CXCR4 ligand, SDF [58].
In fact, premetastatic niche might be “a sleepy niche”, tightly 
regulating the dormancy of disseminated cancer cells [77]. Some 
cellular and molecular factors regulating the dormancy have been 
mentioned above. However, it is becoming clear that niche-based cues 
function only in the context of specific tissues. Another conclusion 
is that maintenance of tissue homeostasis is crucial. Most dormant 
breast cancer cells associate with the abluminal surface of the 
microvasculature of distant organ sites. As long as microvasculature 
is stable, it produces dormancy-inducing factors. Endothelial 
quiescence can be disrupted by e.g. inflammation, wounding and 
ageing, and then signals change to induce tumor cell proliferation 
[77].
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Liver is the target organ for metastasis for many cancers - GI tract, 
breast, pancreas, lung, cutaneous melanoma and sarcomas and some 
progress in understanding the formation of the liver metastatic niche 
has been described. Many environmental factors have been shown to 
play a role, such as active bi-directional communication by mRNA 
in exosomes [78,79], fibroblasts [80], or hepatocyte progenitor cells 
[81].
Inflammation and immune cells are also factors influencing 
dormancy. Breast and lung carcinoma cells selected for their ability to 
persist in a latent state after seeding of distant organ sites succeed in 
evading clearance by NK cells through the repression of various NK 
cell-activating ligands, a program that appears to be tightly coupled 
with entrance into a quiescent state [76]. Recently Albrengues et 
al. [74] showed that bacterial-derived Lipopolysaccharide (LPS), a 
trigger of inflammation, or cigarette smoke (which may carry LPS as 
a contaminant) can activate neutrophils to release their DNA content 
into the lung parenchyma to form Neutrophil Extracellular Traps 
(NETs) that usually capture microorganisms. This activates focal 
adhesion kinase and induces proliferation in dormant DCC [74].
One characteristics of the liver microenvironment that may 
play role in the dormancy control is its immune microenvironment. 
Liver is known to facilitate immune escape [82,83]. Moreover, in the 
aged mice a slower growth of the ocular tumor was seen, but more 
liver metastases due to the lower cytolytic activity of NK cells in the 
liver, and bone marrow derived cells played a role in the heightened 
metastases [84].
The presence of residual UM cells in the bone marrow was 
detected in 39% patients at diagnosis. They were mostly vital 
melanoma cells, documenting that dissemination are an early event 
in uveal melanomas, supporting the dormancy hypothesis [85]. The 
quiescent state of dormant cells contributes to the observed resistance 
to conventional therapies aimed at targeting rapidly diving cells. The 
role of CTC as a negative prognostic marker was demonstrated in 
uveal melanoma patients after a long follow-up period. The number 
of CTC (lower or higher than 10 CTC per 10 mL blood) and the 
presence of CTC clusters correlated significantly with largest basal 
diameter, tumor height, and disease-free and overall survival [61]. 
Both CTC and ctDNA were found to be prognostic in another study. 
CTC count and ctDNA levels were associated with the presence of 
miliary hepatic metastasis, with metastasis volume, and with each 
other. CTC count and ctDNA levels were both strongly associated 
with progression-free survival and overall survival [86].
The exact mechanisms and all the molecular, cellular or 
microenvironmental factors responsible for maintaining dormancy 
or influencing reawakening of cells from dormancy in UM are 
unknown and require intense studies.
Cellular and Molecular Mechanisms 
Associated with UM Metastasis
There is a plethora of molecular factors and pathways shown to 
be connected to metastasis in UM. They are studied either as markers 
of a distant disease, and therefore potentially of prognostic value, 
or as a part of the mechanism responsible for metastatic spread. 
An excellent, detailed analysis of them is presented in other papers 
[87,88]. Several research directions mentioned below seem to be 
worth further studies, especially in the context of animal models.
For example, GNAQ stimulates the transcriptional co-activator 
YAP in human uveal melanoma cells. YAP/TAZ has been shown to 
act as stiffness sensors, regulating mechano-transduction, which is an 
important part of cellular motility. Disruption of the actin cytoskeleton 
diminished both the basal activity of YAP and YAP hyper activation 
[89]. GNAQ mutation also induces viability and migration of uveal 
melanoma cells via Notch signaling activation, which is mediated by 
YAP dephosphorylation and nuclear translocation [90].
Loss of BAP1 expression in UM tumors associated well with 
all of the methods currently used for prognostication and was 
itself predictive of death due to metastasis in uveal melanoma after 
enucleation [91]. Silencing BAP1 in 92.1 cells led to dedifferentiated 
phenotype, characteristic of more invasive class II tumors. BAP1 
depletion also caused a reduction in mRNA levels of neural crest 
migration genes (ROBO1), melanocyte differentiation genes 
(CTNNB1, EDNRB and SOX10) and other genes that are down-
regulated in class 2 tumors [11].
Cellular plasticity and stemness seem to play a role in UM, and 
therefore may be expected to be significant in UM metastasis as 
well, as biomarkers such as beta-catenin, E-cadherin, and hypoxia-
inducible factor 1alpha most strongly associated with the more 
aggressive tumors [92]. BAP1 is necessary for maintenance of 
melanocyte identity in uveal melanoma cells, and that loss of BAP1 
leads to a loss of cell identity and acquisition of a primitive, stem-like 
phenotype [93]. The studies using established UM cell lines (Mel270 
and OMM2.5) revealed their heterogeneity and the presence of a 
CSC-like subpopulation with enhanced self-renewal and proliferative 
capabilities [94]. High cellular plasticity was also found in UM cells 
from short-term primary cultures. The authors concluded that 
inherent changeable phenotype of UM may be responsible for the 
fact that hierarchical CSCs have not been conclusively identified 
in UM [95]. CD133-positive cells, i.e. putative cancer stem cells 
were detected in uveal melanoma. What is interesting they were 
predominantly localized at the invading tumor front, which may be 
a further indication for the tumorigenic and metastatic potential of 
these cells. Other putative stem cell markers (Sox2, Pax6, Musashi, 
ABCB5) also predominantly localized to these areas [96].
Epithelial-to-Mesenchymal Transition (EMT) is a critical cellular 
event for metastasis of malignant tumors of epithelium origin and 
promotes mesenchymal phenotype, leading to intravasation of tumor 
cells into the blood stream or lymphatic vessels with the subsequent 
formation of distant metastases. UM is of neural crest origin, and 
clinically, spindle mesenchymal phenotype (spindle cell) of UM is 
indicative of less aggressive malignancy as compared to the aggressive 
epithelial phenotype. Expression of several EMT factors were studied 
in UM cell lines and tumor samples and it was shown that ZEB1 is 
highly expressed in uveal melanoma cell lines, while two other EMT 
factors, Twist1 and Snail1, were also expressed, but to a lesser degree. 
The genetic down regulation of these factors reduced the invasiveness 
of uveal melanoma cells in vitro, and ZEB1 and Twist1 mRNA levels 
significantly increased in primary tumors with high metastatic 
risk [97]. Chen et al. showed that spindle UM cells can convert to 
epithelioid UM cells both in vivo and in vitro. They pointed out that 
higher levels of ZEB1 propel UM progression by promoting cell 
dedifferentiation, proliferation, local migration and invasion, though 
had little effect on EMT morphology and concluded that ZEB1 is an 
oncogenic factor required for UM growth and metastasis.
Chemokine receptors and their respective ligands, e.g. CXCR4/
CXCL12 is implicated in uveal melanoma metastases. High expression 
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of CXCR4 on UM cells facilitates the accumulation of uveal melanoma 
cells in the liver [98]. It was also shown that ocular microenvironment 
factors induce methylation and down regulation of tumor CXCR4 
expression [99], so perhaps this chemokine role is not dominant in 
UM. Another molecule, c-Met, a receptor for Hepatocyte Growth 
Factor (HGF), promotes invasion and stimulates tumor growth 
through a paracrine effect produced by hepatocytes. High levels of 
soluble c-met were found in blood of patients with metastatic disease 
and suggested to be a possible marker [100]. Crizotinib, an inhibitor 
of c-met, significantly reduced development of metastases in a mouse 
model, suggesting that the inhibition of c-Met activity alone may be 
sufficient to strongly inhibit formation of UM metastasis [101].
Exosomes secreted by tumor cells are one of the paracrine 
signaling ways and research on their role in UM is just beginning. 
Exosomes isolated from liver perfusate of UM metastatic patients 
contained miRNA pattern characteristic of UM cells [102]. UM-
derived exosomes expressing integrin α V/integrin β5 are taken up 
by liver-specific cells to prepare the premetastatic niches and steer the 
liver tropism of UM cells [103].
Hypoxia is one of the factors increasing tumor aggressiveness. 
An increase in Hypoxia-Inducible Factor 1a (HIF-1a) expression was 
seen in more than 60% of UM patients and was significantly associated 
with proliferative and vascular markers, as well as necrosis [104]. 
HIF-1a protein expression was increased in well-vascularized tumor 
regions as well as in four cell lines grown in normoxia. Growth in 
hypoxia significantly increased cellular invasion UM cell lines tested. 
Genetical or pharmacological blockade has negative effects on tumor 
growth and invasion, activation of Notch and MAPK was required 
for full induction of cellular invasion under hypoxic conditions 
[105]. In clinical UM samples an increased expression of HIF1a, and 
a decreased expression of VHL were associated with monosomy 3/
loss of BAP1 expression. The possible mechanism might involve an 
up-regulation of HIF1a due to increase in NF-kB expression with 
BAP1 loss. What is more, HIF1a was associated with the presence of 
macrophages and lymphocytes, also correlating with increased NF-
kB [106].
Conclusion
Metastases remain the main challenge in uveal melanoma 
management due to lack of specific treatment. Despite a marked 
progress in uveal melanoma development has been made, the 
metastatic spread needs further intense research. For example, 
it is well established that the genetic profile of the UM tumors 
characterized by monosomy 3 and bilallelic BAP1 loss is associated 
with the worst prognosis. The growth stages of UM lesions in the liver 
were described, and many potential molecular factors influencing 
the process of metastatic spread and colonizing the liver niche 
are known, however our understanding of this process is far from 
clear. Critical questions on the mechanism of UM cells seeding 
from the primary tumor, homing to the liver, liver invasion, UM 
cell dormancy and dormancy ending need to be answered urgently. 
Only understanding many aspects of UM metastases, including its 
timeline, organ specificity, molecular biology will enable the new 
therapeutic opportunities.
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